Virtual Investor Event on Treatments for Retinitis Pigmentosa to Be Held October 19; Panelists include Kiora Pharmaceuticals, Foundation Fighting Blindness, and Retinal Surgeon Christine Kay, M.D.

Dallas, Texas--(Newsfile Corp. - September 28, 2022) - Stonegate Capital Partners will host a virtual investor event with ophthalmology experts to discuss Retinitis Pigmentosa (RP) and the pipeline of products in development. Participants will include Christine Kay, M.D., Vitreoretinal surgeon and IRD specialist at Vitreoretinal Associates, Eric Daniels, M.D., CDO of Kiora Pharmaceuticals (NASDAQ: KPRX) and Ben Shaberman, Ph.D., from the Foundation Fighting Blindness. The 30 minute event will be held Wednesday, October 19, 2022 at 4:30 PT Eastern Time.

To view the full announcement, including downloadable images, bios, and more, click here^[1].

Key Takeaways:

• Panelists will discuss investigational treatments for RP, ranging from gene and cell therapies to photoresponsive small molecules.
• Retinitis pigmentosa (RP) is a rare, inherited genetic eye disease that causes severe loss of functional vision over time and to date has no cure.
• Panelists will include a leading retinal surgeon, Kiora Pharmaceuticals and Foundation Fighting Blindness.

Click image above to view full announcement.

About Stonegate Capital PartnersStonegate Capital Partners^[2] is a leading advisory firm founded in 1972. We specialize in capital markets advisory with a focus on institutional investor outreach for public and private companies. Our affiliate, Stonegate Capital Markets (Member FINRA/SIPC) provides a full spectrum of investment banking services and equity research.

Contacts:

Erol Girgin214.987.4121erol@stonegateinc.com^[3]

Source: Stonegate, Inc.^[4]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/138681^[5]